


# Polycystic Ovarian Syndrome

## *Diagnostic Recommendations*




# Polycystic Ovarian Syndrome (PCOS)

---


- Most common metabolic and endocrine pathology in the reproductive age female around the world
- Stein and Leventhal initially described it in 1935
- Characterized by –
  - Oligo-ovulation/anovulation
  - Hyperandrogenism
  - Polycystic ovaries
- Signs and symptoms of PCOS include hirsutism, acne, menstrual irregularities, infertility, obesity, and psychiatric disorders such as anxiety and depression.

# Conditions Associated with PCOS

---



# Schema of Etiology & Clinical Features Including Reproductive, Metabolic and Psychosocial Features of PCOS



# Prevalence


- Prevalence ranges around 5% to 15% depending on the diagnostic criteria applied in the world.
- The prevalence of PCOS increases rapidly from 12 to 14 years of age, peaks between 15 and 24, and decreases gradually thereafter, reaching its lowest point before menopause (Zhuang et al., 2014).

*Prevalence  
in India*


Source	Population	NIH/NICHD	Rotterdam	Androgen excess and PCOS society
<b>Beena Joshi, et al</b>	<b>600 Indian (Mumbai)</b>	-	<b>22.5 %</b>	<b>10%</b>
<b>Nidhi R et al</b>	<b>460 Indian (Andhra Pradesh)</b>	-	<b>9.3%</b>	-
<b>Chhabra S et al</b>	<b>1182 Indian Rural (Sevagram)</b>	-	<b>8.4%</b>	-
<b>Balaji S et al</b>	<b>163 Indian (Vellore) Urban 63, Rural 63 Age 12-19yrs</b>	-	<b>18% (U 25%, R 11%)</b>	-

Wang et al. / J Zhejiang Univ-Sci B (Biomed & Biotechnol) 2018 19(5):354-363;  
[http://www.pcosindia.org/files/education/pcos\\_epidemic\\_in\\_india\\_19\\_6\\_2016.pdf](http://www.pcosindia.org/files/education/pcos_epidemic_in_india_19_6_2016.pdf)

# Factors Involved in Pathophysiology of PCOS



# Proposed Natural History of PCOS From Fetal Life to Adulthood



The severity of polycystic ovary syndrome (PCOS) and the evolution of its phenotypic expression result from the impact of environmental influences (both pre- and postnatal) on genetic and epigenetic factors in utero. HA, Hyperandrogenism; GDM, gestational diabetes mellitus; SGA, small for gestational age; LGA, large for gestational age.

# Criteria for Diagnosis of PCOS

---

<i>Clinical finding</i>	<i>National Institutes of Health criteria, 1990 (must have both of the findings marked below)</i>	<i>Rotterdam criteria, 2003 (must have any two of the findings marked below)</i>	<i>Androgen Excess and PCOS Society, 2009 (must have A plus either B or C)</i>
Hyperandrogenism*	X	X	A
Oligomenorrhea	X	X	B
Polycystic ovaries		X	C



# Diagnosis of PCOS in Adults

---

## *2003 Rotterdam ESHRE/ASRM)*

*At least 2 out of 3 criteria:  
(1) oligo- or anovulation  
(2) clinical and/or biochemical  
signs of hyperandrogenism  
(3) PCO*

***Exclusion:*** *congenital adrenal  
hyperplasia, androgen-  
secreting tumors, or Cushing's  
syndrome.*

## *2013 the Endocrine Society*

*At least 2 out of 3 criteria:  
(1) androgen excess  
(2) ovulatory dysfunction  
(3) PCO*

***Exclusion:*** *thyroid disease,  
hyperprolactinemia, or nonclassic  
congenital adrenal hyperplasia.*

# Diagnosis of PCOS in Adolescents

---

## *2003 Rotterdam ESHRE/ASRM)*

- (1) Oligomenorrhea or amenorrhea present for at least 2 years after menarche (or primary amenorrhea at age 16 years);*
- (2) The diagnosis of PCO on ultrasound includes increased ovarian size (>10 cm<sup>3</sup>);*
- (3) Hyperandrogenemia rather than just signs of androgen excess should be documented.*

## *2013 the Endocrine Society*

*Clinical and/or biochemical evidence of hyperandrogenism (after exclusion of other pathologies), and persistent oligomenorrhea.*

# Diagnosis of PCOS in Paediatric Population

## NIH 1990

Requires the simultaneous presence of:

1. Hyperandrogenism (clinical and/or biochemical)
2. Ovarian dysfunction

## 2003 Rotterdam ESHRE/ASRM)

Requires the presence of at least two criteria:

1. Hyperandrogenism (clinical and/or biochemical)
2. Ovulatory dysfunction
3. Polycystic ovarian morphology

## 2006 AES

Requires the presence of hyperandrogenism (clinical and/or biochemical) and either:

1. Ovulatory dysfunction
2. Polycystic ovarian morphology

## 2009 Androgen Excess and PCOS Society

Requires the simultaneous presence of:

1. Hyperandrogenism (clinical and/or biochemical)
2. Ovarian dysfunction (ovulatory dysfunction and/or polycystic ovarian morphology)

# Diagnosis of PCOS in Perimenopause and Menopause

---

*2013 the Endocrine Society*

*Well-documented long-term history of oligomenorrhea and hyperandrogenism during the reproductive years. PCO on ultrasound is supportive.*


# Biochemical Hyperandrogenism – ASRM 2018

---

- Assessment of biochemical hyperandrogenism is most useful in establishing the diagnosis of PCOS and/or phenotype where clinical signs of hyperandrogenism (in particular hirsutism) are unclear or absent.
- Calculated free testosterone, free androgen index, or calculated bioavailable testosterone should be used to assess biochemical hyperandrogenism in the diagnosis of PCOS.
- Androstenedione and dehydroepiandrosterone sulfate (DHEAS) could be considered if total or free testosterone are not elevated; however, these provide limited additional information in the diagnosis of PCOS.

# Reverse Ratio of FSH to LH

- A hallmark laboratory sign of PCOS is a reverse ratio of FSH to LH.
- Normally, an equal ratio of FSH to LH or, FSH being slightly higher than LH is observed.
- In PCOS, the ratio is reversed with a 3:1 of LH:FSH.



*Elevated levels of LH (3x greater than FSH) stimulating increased androgen (testosterone) production by the ovary causing excess hair growth and acne.*


<https://www.acfs2000.com/polycystic-ovarian-disease-pcod.html>

# Anti-mullerian Hormone (AMH)

---

- AMH is the best single serum test for ovarian response management. PCOS is significantly associated with elevated serum AMH both with NIH criteria and with Rotterdam criteria.
- Serum AMH levels improve menopause prediction, monitoring of ovarian damage, and identification of women at risk for PCOS and premature or primary ovarian insufficiency. It provides insight into subphenotypes of PCOS with higher serum AMH predicting longer menstrual cycle length, higher luteinizing hormone (LH) levels, and hirsutism.
- However, it can have dramatic variability due to common, biologic fluctuations within some individuals, use of hormonal contraceptives or other medications, certain surgical procedures, specimen treatment, assay changes, and laboratory calibration differences.

# Diagnostic Algorithm for PCOS





# Key Recommendations for Practice

---

## *Clinical recommendation*

---

All women diagnosed with PCOS should be screened for metabolic abnormalities (e.g., type 2 diabetes mellitus, dyslipidemia, hypertension), regardless of body mass index.

All women with suspected PCOS should be screened for thyroid disease, hyperprolactinemia, and nonclassical congenital adrenal hyperplasia.

A calorie-restricted diet is recommended for all patients with PCOS who are overweight. Weight loss has been shown to have a positive effect on fertility and metabolic profile.

Hormonal contraception (e.g., oral contraceptives) should be used as the initial treatment for menstrual cycle irregularity, hirsutism, and acne in patients with PCOS who are not actively trying to get pregnant.

---

# Screening for Medical Conditions Associated with PCOS

---

## **Suggested screening tests:**


- Lutenising hormone
- Follicle-stimulating hormone
- Total testosterone, sex hormone-binding globulin
- Lipid profile
- Fasting glucose with or without oral glucose tolerance test, glycated haemoglobin
- Serum prolactin
- Thyroid function
- Serum ferritin
- 25-hydroxy vitamin D

## **If clinically indicated:**

- 17-hydroxyprogesterone
- 1 mg overnight dexamethasone suppression or 24-hour urine-free cortisol
- Sleep study

# Tests Done in SRL

TEST	METHOD	CODE
PCOD Panel (LH, FSH, Prolactin, Testosterone (Total & Free), Insulin (Fasting & PP), Glucose (Fasting & PP))	Spectrophotometry/ Chemiluminescence/ Dipstick	1011
AMH (Anti-Müllerian Hormone)/ Müllerian Inhibiting Substance (MIS)	CLIA	1705



Thank You

